There are currently 91 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Cannabidiol in Sickle Cell Disease
Recruiting
Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Icahn School of Medicine at Mount Sinai, Manhattan, New York
Conditions: Sickle Cell Disease
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
Recruiting
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assess... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Alabama, Birmingham (UAB), Birmingham, Alabama +8 locations
Conditions: Sickle Cell Disease
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Recruiting
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Magee Women's Hospital, Pittsburgh, Pennsylvania +4 locations
Conditions: Sickle Cell Disease
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
06/12/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +2 locations
Conditions: Sickle Cell Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
Recruiting
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas +22 locations
Conditions: Sickle Cell Disease, Sickle Cell Anemia
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Recruiting
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Illinois at Chicago College of Medicine, Chicago, Illinois
Conditions: Sickle Cell Disease
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
05/20/2025
Locations: University of California Los Angeles, Los Angeles, California +3 locations
Conditions: Sickle Cell Disease
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
Recruiting
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Gender:
ALL
Ages:
Between 5 years and 50 years
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +3 locations
Conditions: Sickle Cell Disease, Renal Disease, Glomerular Disease
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Recruiting
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how... Read More
Gender:
ALL
Ages:
Between 2 years and 50 years
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey +5 locations
Conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Investigation of the Genetics of Hematologic Diseases
Recruiting
The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic rese... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Recruiting
This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs). SECONDARY OBJECTIVES * To characterize the efficacy of a s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
School Readiness Intervention for Preschool Children With Sickle Cell Disease
Recruiting
The study participant is being asked to take part in this clinical trial, a type of research study, because the participant is a young child with sickle cell disease or the caregiver of a child with sickle cell disease. This study is being done to test a school readiness program for children with sickle cell disease (ages 3.5-6,5 years old). Primary Objective Assess feasibility and acceptability of an adapted school readiness intervention among preschool children (ages 3.5-6.5) diagnosed with... Read More
Gender:
ALL
Ages:
Between 42 months and 78 months
Trial Updated:
05/06/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease